Please login to the form below

Not currently logged in

Mix-and-match COVID-19 vaccines may be more effective

A small study shows a booster shot of J&J’s vaccine six months after a primary course of the Pfizer/BioNTech vaccine may offer more protection

Johnson and Johnson

As booster campaigns against COVID-19 across the world are ramped up to combat a new wave of Delta variant and the threat of the new Omicron variant, data is trickling in on the effectiveness of a mix-and-match approach.

Johnson & Johnson (J&J) has released preliminary results from a small phase 2 study that show a booster shot of its COVID-19 vaccine, Ad26.COV2.S, not only elicits a ‘substantial increase in antibody and T-cell responses’ but that the protection may be greater than a booster with Pfizer/BioNTech’s Comirnaty.

In the study, conducted at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, 65 people who had previously received Comirnaty were given either a third, booster shot of Pfizer/BioNTech’s vaccine or a shot of J&J’s vaccine six months after the primary regimen.

“There is early evidence to suggest that a mix-and-match boosting approach may provide individuals with different immune responses against COVID-19 than a homologous boosting approach,” said Dr Dan Barouch, director of the Center for Virology and Vaccine Research at BIDMC.

“In this preliminary study… there was a comparable increase of antibody responses at week four following the boost and a greater increase of CD8+ T-cell responses with Ad26.COV2.S compared with BNT162b2,” he said.

These phase 2 data align with preliminary results from the UK’s COV-BOOST study published in The Lancet last week which found that ‘all study vaccines boosted antibody and neutralising responses’ following an initial course of the Oxford/AstraZeneca vaccine, sold under the name Covishield or Vaxzevria.

However, the authors noted that “substantial differences in humoral and cellular responses” would “influence policy choices for booster vaccination”.

In the J&J-funded study in Boston, humoral (antibody) responses for a booster of Ad26.COV2.S led to a similar level of neutralising and binding antibodies against the original SARS-CoV-2 strain and both the Delta and Beta variants four weeks following the boost.

However, with a J&J booster dose, antibodies continued to increase for at least four weeks whereas antibodies declined from week two to week four following a booster with Comirnaty.

With cellular (T-cell) responses, its vaccine “appears to lead to a greater increase in CD8+ T-cell responses than boosting with BNT162b2”, said J&J.

“These T-cell response data suggest differences between immune responses following homologous boosting with BNT162b2 and mix-and-match boosting with the Johnson & Johnson COVID-19 vaccine following a primary regimen of BNT162b2,” J&J added.

7th December 2021


COVID-19 Updates and Daily News

Featured jobs


Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...
The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....